Press release
H1 2017 Transforming Growth Factor Beta 1 (TGFB1) Industry Pipeline Review Size, Share, Trend and Analysis Research Study
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310016 .
Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Cardiovascular, Central Nervous System, Genetic Disorders and Respiratory which include indications Fibrosis, Kidney Fibrosis, Liver Fibrosis, Acute Pain, Atherosclerosis, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Chronic Pancreatitis Pain, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hypertrophic Scars, Inflammation, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteoarthritis, Osteogenesis Imperfecta, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Scar, Skin Inflammation, Solid Tumor and Squamous Cell Carcinoma.
The latest report Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2017, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.
Browse the full report @ http://www.orbisresearch.com/reports/index/transforming-growth-factor-beta-1-tgfb1-pipeline-review-h1-2017 .
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
- The report reviews Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310016 .
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Acceleron Pharma Inc
Eli Lilly and Company
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Scholar Rock Inc
Sirnaomics Inc
For any enquires before buying, connect with us @ enquiry@orbisresearch.com
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact sales@orbisresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release H1 2017 Transforming Growth Factor Beta 1 (TGFB1) Industry Pipeline Review Size, Share, Trend and Analysis Research Study here
News-ID: 562924 • Views: …
More Releases from Orbis Research
Blood Purification Devices Market 2023-2028 | Top Players Baxter International, …
Based on the type segment, the portable equipment segment is expected to hold the largest share in Blood Purification Devices in the year 2028. Professionals that are actively involved in the ongoing purification of blood tend to favour portable equipment. Equipment that is portable enables effective emergency care. Additionally, portable equipment is rather space-efficient and compact, which promotes widespread use throughout the blood-purification process. In a manner similar to how…
Clean Beauty Market to Grow at 40.1% CAGR by 2028 - Key Players are Bare Mineral …
Clean beauty is described as beauty and personal care products that are made with the safest possible ingredients and have the lowest possible environmental impacts. Clean beauty pertains to products that are safe, non-toxic, and clearly labelled ingredients Also, the ingredients used are cruelty-free and are screened for non-GMO feedstock and residual pesticides.
Request a pdf brochure @ https://www.orbisresearch.com/contacts/request-sample/6941781
The Clean Beauty Market is valued at USD 5163.17 Million in 2021 and…
Outdoor Power Equipment Market Worth USD 6.49 Bn by 2027 - Industry Trends and S …
The outdoor power equipment generally includes, brush cutters, edger, chain saws, power rakes, and more. Outdoor power equipment is commonly used by end users, such as lawn & plant care providers and landscape service providers, for commercial purposes.
The global outdoor power equipment market in 2021 was valued at US$32.22 billion. The market value is projected to reach US$46.49 billion by 2027. Outdoor power equipment (OPE) is an equipment with small…
Merchant API Market to reach US$119.11 billion by 2027 - Industry Trends, Growth …
The latest research on "Global Merchant API Market: Analysis By Molecular Type, By Segment, By Type, By Type of Synthesis, By End-User, By Region Size And Trends With Impact Of COVID-19 And Forecast up to 2027" have been added to OrbisResearch.com store.
The merchant API market refers to the use of APIs by merchants, or businesses that sell goods and services, to connect their systems and processes with those of other…
More Releases for Transforming
Transforming Lives , Together
Unessa Foundation is a purpose-driven organization committed to transforming lives, together. Built on the belief that unity and compassion are the cornerstones of meaningful change, Unessa empowers individuals and communities through inclusive programs, collaborative efforts, and a people-first approach.
Rooted in dignity, empathy, and impact, our mission is to uplift underrepresented voices, close opportunity gaps, and strengthen human connections that create lasting social change. At Unessa, we see every person as…
Exosome Innovations Transforming Healthcare Solutions
The global exosome diagnostic and therapeutic market is witnessing remarkable growth, with its projected value reaching an astounding USD 22,609.77 million by 2034, up from USD 33.04 million in 2023. This meteoric rise represents a staggering compound annual growth rate (CAGR) of 81.03% from 2024 to 2034. As the market continues to expand, the spotlight is firmly on exosomes, small extracellular vesicles that play a significant role in a variety…
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
Transforming Higher Education Admissions
Radius X, a user-friendly platform for admission automation and data analysis, is now available for higher education providers. Designed to simplify the admissions process, Radius X enhances the student experience through self-service options and automation.
Admissions teams today face growing challenges as they handle more applications and higher expectations from students. Many are overwhelmed by paperwork and manual tasks that take away valuable time. Radius X addresses these struggles by…
Curiotory: Transforming Language Learning
India's ultimate language learning app
Curiotory is a language learning platform dedicated to creating an enjoyable and effective learning experience. With a focus on online language learning, Curiotory empowers learners to achieve fluency and cultural understanding.
Curiotory, a trailblazer in the language learning industry, is proud to announce its continued commitment to providing a unique, immersive, and personalized approach to language education. With a mission to bridge cultural gaps and make…
Transforming Smiles, Transforming Lives: Introducing Dr. Robert Rifkin, the Maes …
Image: https://www.getnews.info/uploads/3cc5ecdc456666ed434d2b2f5410c024.png
Dr. Robert Rifkin, the visionary force behind some of the most iconic smiles worldwide, continues to redefine the standards of cosmetic dentistry. With over four decades of unparalleled expertise, Dr. Rifkin has earned his place as the godfather of cosmetic dentistry, revolutionizing the field with his innovative treatments and unparalleled artistry.
A Legacy of Innovation
For over 40 years, Dr. Robert Rifkin has been at the forefront of cosmetic dentistry in…
